Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Premarket exemption final rule

This article was originally published in The Gray Sheet

Executive Summary

Effective Feb. 14, rule lists all Class I and Class II devices that are exempted from premarket notification under the 1997 FDA Modernization Act. List includes cardiopulmonary bypass accessory equipment and electrode cables, devices which initially had been removed from the list following an FDA proposed rule reclassifying them to Class II and requiring them to meet certain performance standards (1"The Gray Sheet" Nov. 16, 1998, p. 10). The agency explains that as long as these devices met the standard there was no need for them to submit a 510(k), and clarified that this decision would have no effect on the proposed reclassification. On its own initiative, the agency also has added all versions of keratoscopes to the list; previously, keratoscopes using computer software were not considered exempt

Latest Headlines
See All
UsernamePublicRestriction

Register

MT012832

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel